June 17, 2014 — AtheroNova Inc. received a Notice of Issuance for an additional compound for cardiovascular treatments. This patent issuance further exemplifies a plan to develop a broad platform of intellectual property involving atheroma stabilization and reduction, lipid modulation and other metabolic diseases. This issuance continues efforts by the company and its patent counsel in pursuit of numerous patents covering the systemic delivery of naturally occurring bile acids, bile acid synthetics, analogs and conjugates. AtheroNova is a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans.
"This latest patent issuance expands our patent portfolio to now include multiple compounds for addressing atherosclerotic plaque and stands as an important continuation of our goal of being the clear leader in the systemic delivery of bile acids, bile acid synthetics, analogs and conjugates to dramatically enhance cardiovascular and metabolic health," said AtheroNova CEO Thomas W. Gardner. "As our drug development efforts accelerate, the company will continue to pursue additional pending patent applications for systemic delivery of our family of bile acids and bile acid derivatives. The development of our platform is significantly advanced by this achievement."
For more information: www.atheronova.com
July 10, 2024 
